abstract |
The present invention relates to compounds of formula (I) that are potent selective agonists of the EP 4 subtype of prostaglandin E2 receptor, those in the treatment of glaucoma and other diseases associated with elevated intraocular pressure in the patient's eye Relating to use or formulation. Embedded image |